BRAND NAMES
 MECHANISM OF ACTION
Vandetanib is an anti-cancer drug. It acts as a kinase inhibitor of a number of cell receptors, mainly the vascular endothelial growth factor receptor (VEGFR), the epidermal growth factor receptor (EGFR), and the RET-tyrosine kinase.
Vandetanib is indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with locally advanced or metastatic disease who are ineligible for surgery.
In patients with indolent, asymptomatic or slowly progressing disease Vandetanib should be used only after careful consideration of the treatment related risks of Vandetanib.
The recommended dose is 300 mg once daily with or without food.
Dosage reduction to 200 mg (two 100 mg tablets) and then to 100 mg may be necessary in the event of severe toxicities or QTc interval prolongation.
The starting dose is 200 mg in patients with moderate to severe renal impairment.
- Patients with congenital long QT syndrome
- Avoid the use of strong CYP3A4 inducers because they may decrease Vandetanib exposure.
- Avoid the use of agents that prolong the QT interval.
 PREGNANCY AND LACTATION
 SIDE EFFECTS
The most common adverse drug reactions seen with Vandetanib are diarrhea/colitis, rash, acneiform dermatitis, hypertension, nausea, headache, upper respiratory tract infections, decreased appetite and abdominal pain